Articles tagged with Pancreatic Cancer
Researchers have uncovered a potential strategy to eliminate cancer cells that survive KRAS inhibition, preventing relapse. By targeting the metabolic pathways that support the survival of drug-tolerant persister cells, treatment regimens could be designed to shrink tumors and prevent cancer recurrence.
A multidisciplinary panel of experts recommends evidence-based screening and surveillance strategies for pancreatic cancer in high-risk populations, aiming to improve early diagnosis and survival. The guidelines specify starting ages, surveillance intervals, imaging modalities, surgical indications, and lifestyle modifications.
Pre-retrieval imaging is revolutionizing liver transplantation by improving graft selection, reducing uncertainty, and supporting better surgical planning. Imaging modalities like ultrasound, CT, and MRI offer distinct strengths and limitations in evaluating liver graft quality, vascular anatomy, and biliary variants.
Researchers have identified IL1RAP as a key player in the tumor-driven inflammatory network that helps pancreatic cancer resist treatment. Blocking this receptor may help break down tumors and improve response to combination therapy.
Researchers at Salk Institute uncover an unexpected role for HDAC enzymes in controlling critical genes involved in DNA repair, making pancreatic cells more vulnerable to therapies that induce DNA damage. This finding paves the way for new treatment strategies combining entinostat with DNA-damaging therapies.
Scientists at VUB mapped healthy pancreas cells down to the cellular level, discovering rare cells with properties similar to aggressive tumour cells. This fundamental discovery may offer opportunities for early detection of pancreatic cancer, currently one of the most difficult diseases to treat.
Researchers investigated polyisoprenylated cysteinyl amide inhibitors (PCAIs) for their anticancer effects on pancreatic cancer cells with KRAS mutations. The compounds demonstrated strong activity against cell survival, migration, and invasion pathways. PCAI treatment caused hyperactivation of MAPK and PI3K/AKT pathways, leading to ox...
A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.
The AGA GI Opportunity Fund invests in Amplified Sciences to advance PanCystPro, a next-generation diagnostic assay for improving pancreatic cyst risk assessment. The funding supports completion of a pivotal real-world observational study and expansion of commercial partnerships.
Researchers at UMass Amherst have designed a new therapy that combines engineered Salmonella bacteria with oncolytic viruses to target liver and pancreatic cancer. The treatment showed promising results in animal models, leading to significant tumor reduction and improved survival rates.
Researchers at IRB Barcelona used AI to design new chemical entities that selectively target specific cell types, demonstrating superior activity compared to conventional screening strategies. The methodology, called phenotypic discovery, uses observable responses in cells rather than a specific molecular target.
The study found high-risk associations between alcohol use and all ten cancers examined, with risk increasing progressively as intake rose. Low-to-moderate drinking was associated with lower disease risk for type 2 diabetes, Alzheimer's disease, ischemic heart disease, and stroke.
Researchers highlight latest developments in pathology, diagnosis, and treatment of MASLD and IPFD, revealing correlations with chronic diseases like liver cancer and pancreatic cancer. Innovative treatments, such as AI-driven approaches and organ-targeted therapies, show promise for precision prevention and therapy.
A study published in the New England Journal of Medicine shows an investigational targeted therapy, daraxonrasib, significantly extends overall survival for patients with metastatic pancreatic cancer, reducing death risk by 60%, compared to standard chemotherapy.
A phase 3 trial shows daraxonrasib, an oral RAS(ON) multi-selective inhibitor, improves overall and progression-free survival compared to chemotherapy in patients with metastatic pancreatic cancer. The treatment also demonstrated substantial tumor shrinkage or disappearance in patients with a known RAS G12 mutation.
Researchers found that a vitamin D analog reduced fibroblast activation and increased T cell infiltration in pancreatic tumors, improving chemotherapy responses and progression-free survival. Patients with high vitamin D receptor expression also had longer overall survival.
Researchers at Memorial Sloan Kettering Cancer Center have uncovered promising combination therapies for a rare childhood brain tumor by analyzing patient samples, cell models, and laboratory data. The study found that cancer cells can develop workarounds to evade targeted RAS therapies, highlighting the need for new treatment strategies.
Researchers will present multiple studies with practice-changing results in various cancers, including pancreatic, prostate, breast, and multiple myeloma. The findings include new treatment strategies and the potential impact of lifestyle factors.
Researchers have discovered that precursor lesions in the pancreas, often considered a step towards cancer, do not undergo malignant transformation if they lack a specific microenvironment. The team used advanced technologies to isolate and analyze single cells from over 150 donated pancreases, finding that the microenvironment surroun...
A lower CA19-9 cutoff of 7 units/mL can identify patients with pancreatic cancer who have high-risk disease despite low biomarker levels. This dual-threshold model helps distinguish between true low tumor burden and Lewis antigen-negative status, improving prognostic assessment.
A new study published in JAMA Network Open found that patients with low-risk pancreatic cystic lesions have a high risk of developing pancreatic cancer. The study highlights the need for long-term personalized surveillance strategies for these patients, which could enable earlier detection and treatment of the disease.
A phase 1/2 trial of daraxonrasib, a RAS(ON) multi-selective inhibitor, demonstrated safety and broad activity against RAS-mutant metastatic pancreatic cancer. The drug showed promising signs of activity, with approximately 30% of patients experiencing an objective response and 90% experiencing disease control.
The Phase 1/2 trial demonstrated a 29% response rate and median overall survival of 15.6 months, outperforming historical chemotherapy response rates. Daraxonrasib targets RAS in its 'on' state and has shown durable responses with a manageable safety profile.
A study published in Cancer Medicine reveals that the same genes active in pancreatic cancer are also linked to obesity and diabetes, driving inflammatory and immune pathways. This discovery helps explain poorer cancer outcomes for those with metabolic disease and offers new avenues for targeted treatment.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
Researchers at Trinity College Dublin have published a comprehensive review of pancreatic cancer, explaining why it's resistant to treatment and where new hope may emerge. The study identifies multiple biological systems interacting to drive the disease's growth and suggests combination-based treatments targeting multiple hallmarks of ...
Researchers at OHSU have developed a sophisticated blood test that can detect early signs of pancreatic cancer with a 97% accuracy rate, distinguishing it from benign conditions. The technique uses nanoparticles shed by tumors into blood, offering a non-invasive way to identify the disease.
The Mayo Clinic AI model detects pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis, identifying subtle signs of disease. The model identified 73% of prediagnostic cancers at a median of about 16 months before diagnosis.
A team of researchers has developed a 'tumor-on-a-chip' system designed to recreate the complex environment surrounding pancreatic tumors. The system, which combines patient-derived organoids with microfluidic technology, closely mimics the behavior of human pancreatic tumors and demonstrates potential for studying immune responses.
An AI model called REDMOD can pick up the very early subtle tissue changes of pancreatic ductal adenocarcinoma, which conventional imaging and the human eye find difficult to detect. The model detected 'invisible' signature of pre-clinical pancreatic cancer an average of 475 days before clinical diagnosis.
A first-in-human clinical trial found that setidegrasib, a targeted therapy drug, demonstrated early antitumor activity in advanced lung and pancreatic cancers. The therapy shrank tumors and delayed disease progression in some patients, providing a potential new treatment approach for KRAS G12D-driven cancers.
Researchers have discovered a vulnerability in pancreatic cancer that could be targeted as a potential therapy. Damaged mitochondria leak double-stranded RNA within cancer cells, causing inflammation that fuels cancer growth.
A new composite scoring system, HOST-Factor, quantifies the functional state of the tumor microenvironment in pancreatic cancer. The study demonstrates the effectiveness of pulsed low-dose-rate chemoradiation in shifting the tumor microenvironment from a tumor-promoting to a tumor-restricting state.
Researchers developed an electrochemical sensor to detect pancreatic cancer at low concentrations, improving accessibility and effectiveness of treatment. The device identifies CA19-9 protein, a key biomarker for the disease, allowing for early diagnosis and potentially increasing survival rates.
A recent study published in Cell reveals the molecular mechanisms underlying the transformation of benign pancreatic cells into malignant tumors. Researchers identified a subset of precancerous cells that closely resemble tumor cells, characterized by high oncogenic drive and strongly activated tumor-suppressors. This discovery offers ...
Researchers from Penn Medicine will showcase progress in CAR T cell therapies for solid tumors, as well as a multi-chain CAR T cell therapy for ovarian cancer. The presentation also highlights a new strategy targeting pancreatic cancer before it forms and at-home cervical cancer testing.
A phase 2 clinical trial shows that a new drug, elraglusib, when combined with chemotherapy, doubles one-year survival rates in pancreatic cancer patients, reducing the risk of death by 38%. The study is a rare success in showing a survival benefit applicable to a broad population.
Researchers at OHSU have uncovered that pancreatic tumors co-opt regulatory immune cells, leading to resistance against immunotherapy. A promising strategy involves reprogramming these cells to support anti-tumor activity, potentially making immunotherapy viable for treatment-resistant cancers.
Researchers at UT MD Anderson have made significant advancements in cancer care, including a blood-based biomarker for cancer risk in people with Lynch Syndrome and a new target to sensitize pancreatic tumors to immunotherapy. The studies also identified a strategy to overcome radiation therapy resistance in lung cancer.
UCLA investigators present new research on targeted drug delivery for colorectal cancer, COVID-19's impact on breast cancer outcomes, and AI in cancer diagnosis. These studies offer insights into overcoming drug resistance, enhancing immune responses, and improving outcomes for patients with difficult-to-treat cancers.
A study published in Cancer Research has identified DPY30 as an epigenetic target that can sensitize pancreatic tumors to immunotherapy. By modulating DNA replication stress, DPY30 promotes the addition of activation signals at stressed replication forks, supporting cancer cell survival and proliferation.
Researchers have developed a new CAR T therapy that targets tumor-supporting cells in pancreatic cancer, paving the way for a potentially safer and more effective treatment. The therapy uses lipid nanoparticles to deliver CAR instructions directly to patient T cells, resulting in higher expression rates and improved efficacy compared t...
A study by researchers at Institute of Science Tokyo has identified a key gene, DOCK10, involved in abnormal insulin secretion in insulinomas. The findings pave the way for novel diagnostic biomarkers and treatment options.
A new study has identified a PRRX2+ epithelial cell/SPP1+ macrophage axis that promotes gemcitabine resistance via TGF-β signaling in pancreatic cancer. The study suggests that targeting this cellular communication network may be key to overcoming drug resistance.
The Sylvester Cancer Tip Sheet for March 2026 highlights the importance of genetic testing for cancer risk assessment. Researchers have made significant progress in developing new treatments, including mRNA-based immunotherapy for colorectal and pancreatic cancers. Additionally, the Dolphins Cancer Challenge has surpassed $100 million ...
Researchers developed an experimental therapy to target microscopic precancerous lesions in the pancreas, which nearly doubled survival in mouse models of pancreatic ductal adenocarcinoma. Long-term treatment with the therapy tripled median overall survival time compared to untreated mice.
Researchers found that depleting fibrinogen, a clotting protein, slows down pancreatic cancer by shrinking tumors and reducing liver metastasis. Fibrinogen contributes to tumor growth and environment, and its depletion changes tumor cells to alter behavior and aggressiveness.
Researchers at OHSU found that sympathetic nerves support pancreatic tumor growth by communicating with cancer cells and nearby fibroblasts. The study suggests that removing these nerves may lead to smaller tumors, particularly in female mice.
Researchers identified a key gene GATA6 that helps control the 'switch' between aggressive and manageable states in pancreatic cancer cells. By targeting this pathway, combination therapies with standard chemotherapy may improve treatment outcomes.
Researchers found that early precancerous cells in pancreas gather into specific clusters and interact with immune cells, weakening the body's ability to fight them. The study provides fresh insight into how pancreatic cancer may begin taking shape years before it is clinically detected.
A new study analyzing 519 patients with cancer reveals that financial toxicity significantly impacts not only finances but also psychological resources like hope and social support. As these resources weaken, overall life satisfaction declines.
The ESE and ESPE have launched a landmark Joint Clinical Practice Guidance to support structured and effective transition of young people with endocrine conditions. The Guidance provides practical, evidence-based recommendations to ensure continuity, safety and quality of care during this critical phase in a patient's life.
A new UCLA study found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer. The combination treatment helped patients live long enough to reach surgery, shrank tumors, and produced encouraging survival outcomes.
A new study shows that pancreatic cancer cells' ability to detect the extracellular matrix determines their growth rate and response to chemotherapy. The researchers found that cells detecting ECM have low autophagy levels and high growth rates, while those farther away from ECM have high autophagy levels and can survive chemotherapy.